JP Morgan Chase
STLN

JP Morgan Chase’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

JP Morgan Chase’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Sell
370,177
-16,601
-4% -$50.9K ﹤0.01% 4583
2025
Q4 		$1.38M Buy
386,778
+362,349
+1,483% +$1.34M ﹤0.01% 4385
2025
Q3 		$85.3K Sell
24,429
-3,506
-13% -$12K ﹤0.01% 5989
2025
Q2 		$57.3K Buy
27,935
+27,881
+51,631% +$69.7K ﹤0.01% 5865
2025
Q1 		$62 Sell
54
-112
-67% -$87 ﹤0.01% 6948
2024
Q4 		$51 Sell
166
-5
-3% -$1 ﹤0.01% 7130
2024
Q3 		$56 Buy
171
+1
+0.6% – ﹤0.01% 7101
2024
Q2 		$78 Sell
170
-8,596
-98% -$7.34K ﹤0.01% 6941
2024
Q1 		$13.8K Buy
8,766
+8,646
+7,205% +$16.4K ﹤0.01% 6292
2023
Q4 		$245 Buy
120
+20
+20% +$35 ﹤0.01% 7030
2023
Q3 		$140 Buy
100
+58
+138% +$60 ﹤0.01% 6877
2023
Q2 		$23 Sell
42
-27,497
-100% -$14.5K ﹤0.01% 6783
2023
Q1 		$19K Buy
27,539
+7,801
+40% +$9.95K ﹤0.01% 5987
2022
Q4 		$32K Buy
19,738
+875
+5% +$2.46K ﹤0.01% 5749
2022
Q3 		$87K Buy
18,863
+8,822
+88% +$51.9K ﹤0.01% 5347
2022
Q2 		$51K Buy
10,041
+9,641
+2,410% +$70.2K ﹤0.01% 5651
2022
Q1 		$3K Sell
400
-3,400
-89% -$22.9K ﹤0.01% 6387
2021
Q4 		$37K Sell
3,800
-457,820
-99% -$4.07M ﹤0.01% 6045
2021
Q3 		$4.58M Sell
461,620
-100
-0% -$993 ﹤0.01% 3111
2021
Q2 		$4.59M Sell
461,720
-64,400
-12% -$648K ﹤0.01% 3129
2021
Q1 		$5.24M Sell
526,120
-73,880
-12% -$787K ﹤0.01% 2936
2020
Q4 		$6.48M Sell
600,000
-100
-0% -$1.03K ﹤0.01% 2590
2020
Q3 		$6.23M Buy
+600,100
New +$6.23M ﹤0.01% 2382

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's STLN Position: Q1 2026 in Review

JP Morgan Chase reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 4.3% in Q1 2026, selling an estimated $50.9K and leaving 370,177 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #4583.

JP Morgan Chase first reported a position in STLN in Q3 2020 and has held it in 23 quarters since. The position peaked at $6.48M in Q4 2020. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • JP Morgan Chase held 370,177 shares of Starling Oncology Institute, Inc. Common Stock worth $1.05M as of Q1 2026.
  • JP Morgan Chase sold 16,601 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $50.9K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4583 holding.
  • JP Morgan Chase first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Starling Oncology Institute, Inc. Common Stock position peaked at $6.48M in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.